Chronic cerebral hypoperfusion (CCH) plays an important role in the occurrence and development of vascular dementia (VD). Recent studies have indicated that multiple stages of immune-inflammatory response are involved in the process of cerebral ischemia, drawing increasing attention to immune therapies for cerebral ischemia. This study aims to identify potential immune therapeutic targets for CCH using bioinformatics methods from an immunological perspective. We identified a total of 823 differentially expressed genes associated with CCH, and further screened for 9 core immune-related genes, namely RASGRP1, FGF12, SEMA7A, PAK6, EDN3, BPHL, FCGRT, HSPA1B and MLNR. Gene enrichment analysis showed that core genes were mainly involved in biological functions such as cell growth, neural projection extension, and mesenchymal stem cell migration. Biological signaling pathway analysis indicated that core genes were mainly involved in the regulation of T cell receptor, Ras and MAPK signaling pathways. Through LASSO regression, we identified RASGRP1 and BPHL as key immune-related core genes. Additionally, by integrating differential miRNAs and the miRwalk database, we identified miR-216b-5p as a key immune-related miRNA that regulates RASGRP1. In summary, the predicted miR-216b-5p/ RASGRP1 signaling pathway plays a significant role in immune regulation during CCH, which may provide new targets for immune therapy in CCH.
Humans ; Computational Biology/methods* ; Brain Ischemia/therapy* ; Immunotherapy ; MicroRNAs/genetics* ; Signal Transduction ; Dementia, Vascular/genetics* ; Chronic Disease

Objective:To explore the anal function and postoperative complications of 2-stage Turnbull-Cutait pull-through coloanal anastomosis (TCA) for low rectal cancer.Methods:Patients undergoing radical rectal cancer resection from Feb 2023 to Nov 2024 in the First Hospital of Jilin University were divided into the TCA surgery group and the low anterior resection combined with prophylactic stoma (LAR) surgery group.Results:Among the 102 patients, there were 50 cases in the TCA group and 52 cases in the LAR group. In the single-arm analysis of the TCA group, the overall complication rate was 44%. The incidence rates of severe LARS at 1 month, 3 months, and 6 months after surgery were 97%, 77%, and 64% respectively. There was no significant difference in the complication rate within 30 days after surgery between the two groups,(44% vs. 38%, χ2=0.135, P>0.05). There was no significant difference in the incidence rate of severe LARS between the TCA group and the LAR group (77% vs. 69%, χ2=0.202, P>0.05), and there was not significant difference in the incidence rate of severe LARS between the two groups at the 6th month after surgery,(64% vs. 48%, χ2=1.132, P>0.05). Conclusion:In patients who underwent TCA surgery, the LARS symptoms gradually decreased over time. Compared with patients undergoing low anterior resection and stoma reversal, there were no significant differences in complications within 30 days after surgery and LARS symptoms within half a year.

Objective To construct and verify an early prediction model for visual benefit of diabetic macular edema(DME)after anti-vascular endothelial growth factor(VEGF)treatment based on clinical data,optical coherence tomo-graphy angiography(OCTA),serum brain tissue aquaporin-4(AQP4)mRNA and total bilirubin(TBIL)levels.Methods A total of 480 patients(480 eyes)with DME treated in the First People's Hospital of Zigong City from October 2021 to March 2024 were selected and divided into a modeling set(320 cases)and a validation set(160 cases)at a ratio of 2∶1.According to the visual benefit after anti-VEGF treatment,patients in the modeling set were further divided into a benefit group(80 cases)and a non-benefit group(240 cases).The baseline data of the two groups of patients were collected,and the factors influencing visual benefits in DME patients after anti-VEGF treatment were analyzed.An early prediction model was constructed and validated both internally and externally.Results The inter-group comparison results showed that the diabetes duration in the non-benefit group was longer than that in the benefit group(P＜0.05).The proportion of smokers,the best corrected visual acuity(BCVA),the minimum resolution angle(logMAR)vision,hemoglobin A1c(HbAlc)and AQP4 mRNA levels were higher in the non-benefit group than those in the benefit group(all P＜0.05).The foveal retinal deep capillary plexus blood flow density(DCP-VD),central macular thickness(CMT),and TBIL levels were lower in the non-benefit group than those in the benefit group(all P＜0.05).The least absolute shrinkage and selection operator(LAS-SO)-Logistic regression analysis showed that the factors influencing visual benefit in DME patients after anti-VEGF treat-ment were CMT,BCVA(logMAR),HbAlc,AQP4 mRNA levels,foveal DCP-VD,and TBIL levels.The predictive risk con-sistency index of the nomogram model constructed based on the above-mentioned influencing factors for visual benefit pre-diction after anti-VEGF treatment was 0.844.The receiver operating characteristic(ROC)curve showed that the area un-der the ROC curve(AUC)of the model was 0.844(95％ CI:0.797-0.891)in the modeling set and 0.898(95％ CI:0.847-0.949)in the validation set.The decision analysis curve showed that when the high-risk threshold of the modeling set ranged between 0 and 82％ and that of the validation set ranged between 0 and 100％,the model could bring net clinical benefits.Conclusion CMT,BCVA(logMAR),HbAlc,AQP4 mRNA levels,foveal DCP-VD,and TBIL levels are the fac-tors influencing visual benefit in DME patients after anti-VEGF treatment.The visual benefit prediction model constructed based on these factors has high accuracy and stability,and can be used as an effective tool for clinical prediction of visual benefit after treatment.

Objective To construct and verify an early prediction model for visual benefit of diabetic macular edema(DME)after anti-vascular endothelial growth factor(VEGF)treatment based on clinical data,optical coherence tomo-graphy angiography(OCTA),serum brain tissue aquaporin-4(AQP4)mRNA and total bilirubin(TBIL)levels.Methods A total of 480 patients(480 eyes)with DME treated in the First People's Hospital of Zigong City from October 2021 to March 2024 were selected and divided into a modeling set(320 cases)and a validation set(160 cases)at a ratio of 2∶1.According to the visual benefit after anti-VEGF treatment,patients in the modeling set were further divided into a benefit group(80 cases)and a non-benefit group(240 cases).The baseline data of the two groups of patients were collected,and the factors influencing visual benefits in DME patients after anti-VEGF treatment were analyzed.An early prediction model was constructed and validated both internally and externally.Results The inter-group comparison results showed that the diabetes duration in the non-benefit group was longer than that in the benefit group(P＜0.05).The proportion of smokers,the best corrected visual acuity(BCVA),the minimum resolution angle(logMAR)vision,hemoglobin A1c(HbAlc)and AQP4 mRNA levels were higher in the non-benefit group than those in the benefit group(all P＜0.05).The foveal retinal deep capillary plexus blood flow density(DCP-VD),central macular thickness(CMT),and TBIL levels were lower in the non-benefit group than those in the benefit group(all P＜0.05).The least absolute shrinkage and selection operator(LAS-SO)-Logistic regression analysis showed that the factors influencing visual benefit in DME patients after anti-VEGF treat-ment were CMT,BCVA(logMAR),HbAlc,AQP4 mRNA levels,foveal DCP-VD,and TBIL levels.The predictive risk con-sistency index of the nomogram model constructed based on the above-mentioned influencing factors for visual benefit pre-diction after anti-VEGF treatment was 0.844.The receiver operating characteristic(ROC)curve showed that the area un-der the ROC curve(AUC)of the model was 0.844(95％ CI:0.797-0.891)in the modeling set and 0.898(95％ CI:0.847-0.949)in the validation set.The decision analysis curve showed that when the high-risk threshold of the modeling set ranged between 0 and 82％ and that of the validation set ranged between 0 and 100％,the model could bring net clinical benefits.Conclusion CMT,BCVA(logMAR),HbAlc,AQP4 mRNA levels,foveal DCP-VD,and TBIL levels are the fac-tors influencing visual benefit in DME patients after anti-VEGF treatment.The visual benefit prediction model constructed based on these factors has high accuracy and stability,and can be used as an effective tool for clinical prediction of visual benefit after treatment.

Objective:To explore the anal function and postoperative complications of 2-stage Turnbull-Cutait pull-through coloanal anastomosis (TCA) for low rectal cancer.Methods:Patients undergoing radical rectal cancer resection from Feb 2023 to Nov 2024 in the First Hospital of Jilin University were divided into the TCA surgery group and the low anterior resection combined with prophylactic stoma (LAR) surgery group.Results:Among the 102 patients, there were 50 cases in the TCA group and 52 cases in the LAR group. In the single-arm analysis of the TCA group, the overall complication rate was 44%. The incidence rates of severe LARS at 1 month, 3 months, and 6 months after surgery were 97%, 77%, and 64% respectively. There was no significant difference in the complication rate within 30 days after surgery between the two groups,(44% vs. 38%, χ2=0.135, P>0.05). There was no significant difference in the incidence rate of severe LARS between the TCA group and the LAR group (77% vs. 69%, χ2=0.202, P>0.05), and there was not significant difference in the incidence rate of severe LARS between the two groups at the 6th month after surgery,(64% vs. 48%, χ2=1.132, P>0.05). Conclusion:In patients who underwent TCA surgery, the LARS symptoms gradually decreased over time. Compared with patients undergoing low anterior resection and stoma reversal, there were no significant differences in complications within 30 days after surgery and LARS symptoms within half a year.

OBJECTIVE To investigate the variations in taste， aroma and volatile organic compounds of Rhei Radix et Rhizoma decoction pieces derived from different sources， and to identify their origins. METHODS The flavor， odor and volatile organic compounds of Rhei Radix et Rhizoma decoction pieces from different sources were compared and analyzed by using electronic tongue， electronic nose， and gas chromatography-ion mobility spectrometry （GC-IMS）. Principal component analysis （PCA）， partial least squares-discriminant analysis （PLS-DA）， orthogonal partial least squares discriminant analysis （OPLS-DA） and Fisher discriminant analysis were employed to identify the origins of Rhei Radix et Rhizoma decoction pieces and establish the basis discrimination criteria. RESULTS The differences in taste of Rhei Radix et Rhizoma decoction pieces from 3 origins were primarily characterized by bitterness， astringency， and bitter-astringent aftertaste. In terms of smell， variations were mainly observed in inorganic sulfides， organic sulfides containing aromatic components， methane and other short-chain alkanes， alcohols， ethers， aldehydes and ketones， as well as nitrogen oxides. Differentially volatile organic compounds mainly consisted of alcohols， aldehydes and ketones. Furthermore， the samples from 8 batches could be effectively classified into 3 categories.Three types of Rhei Radix et Rhizoma decoction pieces can be effectivily identified based on the peak intensity ratio between volatile substances. For example， when the peak intensity of 2-acetylfuran was 3-19 times that of isobutyric acid [dimer]， it was considered as Rheum officinale Baill. CONCLUSIONS The discriminant models established in this study， along with the criteria for determining the origins based on the peak intensity ofcharacteristic volatile compounds， can be utilized for the identification of Rhei Radix et Rhizoma decoction pieces.

Clinicians need to focus on various points in the diagnosis and treatment of insomnia.This article prescribed the treatment protocol based on the unique features,such as insomnia in the elderly,women experiencing specific physiologi-cal periods,children insomnia,insomnia in sleep-breathing disorder patients,insomnia in patients with chronic liver and kidney dysfunction.It pro-vides some reference for clinicians while they make decision on diagnosis,differentiation and treat-ment methods.

Objective:The time to local recurrence of rectal cancer affects patient prognosis.Our study aimed to establish a clear threshold to distinguish between early and late recurrence and analyze their risk and prognostic factors.Methods:We conducted a retrospective se-lection and analysis of clinical data from 111 patients with locally recurrent rectal cancer(LRRC)who underwent proctectomy at Tianjin Med-ical University Cancer Institute&Hospital between January 2006 and December 2019.The minimum P-value approach and Log-rank test were used to determine the cut-off values of early recurrence(ER)and late recurrence(LR).Risk factors for early recurrence were analyzed using Logistic regression models,and prognostic factors associated with additional surgery were assessed using Cox proportional hazards models.Results:Based on the minimum P value approach,the optimal interval to distinguish early from late recurrence was 26 months(P<0.001).In the ER cohort,the median recurrence-free survival(RFS)was 14.1 months and post-recurrence survival(PRS)was 23.7 months.The median RFS of LR patients was 33.4 months,whereas the median PRS was 35.8 months.The 5-year survival rates in the ER and LR groups were 32.5%and 57.1%,respectively(P<0.001).In the univariate analysis,poor differentiation,positive lymph nodes,presence of lymphovascular invasion,and absence of radiotherapy enhanced the likelihood of early recurrence.Furthermore,only radiotherapy caused a significant difference in the multivariate analysis.Conclusions:Early recurrence of rectal cancer can be defined as recurrence within 26 months after radical surgery,and patients with early recurrence have a poorer prognosis.

Objective To investigate the association between clonal hematopoiesis of indeterminate potential(CHIP)and the severity of coronary artery lesions in coronary heart disease(CHD)patients with renal insufficiency.Methods A case-control trial was conducted on 70 CHD patients with renal insufficiency admitted in Chongqing Emergency Medical Center(Affiliated Central Hospital of Chongqing University)and Department of Cardiovascular Diseases of the First Affiliated Hospital of Chongqing Medical University from December 2023 to July 2024.According to the median Gensini score,they were classified into the Gensini score＜44 group(n=34)and ≥44 group(n=36),and based on carrying CHIP mutation or not,they were divided into CHIP group(n=23)and non-CHIP group(n=47).The differences in clinical data were compared between the above 2 pair groups respectively.Binary logistic regression analysis was used to assess the relationship between CHIP status and the severity of coronary artery lesions.Results Compared with the Gensini score＜44 group,the Gensini score ≥44 group had a higher CHIP carriage rate(17.2％vs 47.6％,P=0.008)as well as NT-proBNP level(767 vs 3 480 ng/L,P=0.039).Binary logistic regression analysis showed that CHIP status was still associated with higher Gensini scores after adjustment of NT-proBNP(OR=3.935,95％CI=1.153～13.435,P=0.029).Further CHIP grouping results suggested that the patients in the CHIP group had higher Gensini score(48 vs 38,P=0.004),larger proportion of 3-vessle disease(52.2％vs 25.5％,P=0.040),and lower left ventricular ejection fraction(55.0％vs 58.0％,P=0.042)than those in the non-CHIP group.Conclusion CHIP is an independent risk factor for severe coronary artery disease in CHD patients with renal insufficiency.

Objective:To investigate the characteristics of 18F-FDG and 18F-9-fluoropropyl-(+ )-dihydrotetrabenazine (FP-(+ )-DTBZ; short for DTBZ) brain vesicular monoamine transporter type 2 (VMAT2) PET/CT imaging and analyze its clinical diagnostic value in Parkinson′s disease (PD) patients with or without rapid eye movement sleep behaviour disorder (RBD). Methods:From July 2022 to June 2023, 50 patients clinically confirmed with primary PD who underwent 18F-FDG and 18F-DTBZ PET/CT imaging in the First Affiliated Hospital of Zhengzhou University were prospectively collected. Among them, 18 patients with PD accompanied by RBD (PD-RBD(+ ) group; 16 males, 2 females, age (59.2±9.3) years); 32 patients without RBD (PD-RBD(-) group; 16 males, 16 females, age (57.7±10.2) years). Moreover, 10 healthy controls matched with the age of PD patients were included (5 males, 5 females, age (60.3±9.6) years). 18F-DTBZ specific uptake ratio (SUR) of bilateral striatum, caudate nucleus, anterior putamen, posterior putamen, nucleus accumbens, substantia nigra and other brain regions were obtained with occipital cortex as the reference region. Striatal anterior-posterior gradient and other related semi-quantitative indicators were calculated according to the corresponding formula. One-way analysis of variance (the least significant difference (LSD)- t test), Kruskal-Wallis rank sum test (Bonferroni correction), independent-sample t test and Mann-Whitney U test were used to analyze the data. Pearson correlation and Spearman rank correlation analyses were used to evaluate the correlations. ROC curve analysis was also performed. The differences in global glucose metabolism in two groups were compared using statistical parametric mapping (SPM). Results:PD-RBD(+ ) group had a significantly lower Mini-Mental State Examination (MMSE) or PD Sleep Scale (PDSS) score than PD-RBD(-) group ( z values: -3.12, -3.08, both P<0.01), and its contralateral striatal anterior-posterior gradient of the predominantly affected limbs was significantly lower than that in PD-RBD(-) group ( t=-2.73, P=0.009). SPM analysis showed that the glucose metabolism in the contralateral prefrontal lobe was higher than that in the PD-RBD (-) group ( t values: 3.11-3.57, all P<0.001). 18F-DTBZ SUR in the bilateral striatum, caudate nucleus, anterior putamen, posterior putamen, nucleus accumbens, substantia nigra were considerably lower in both groups compared to the healthy control group ( F values: 6.24-147.61, H values: 8.66-24.43, all P<0.05; post-hoc: LSD- t test, Bonferroni correction, all P<0.01). In the PD-RBD(-) group, contralateral striatal anterior-posterior gradient were negatively correlated with unified PD Rating Scale (UPDRS) score and modified Hoehn-Yahr (mH-Y) stage ( r=-0.35, P=0.048; rs=-0.39, P=0.026). The AUC for distinguishing PD-RBD(+ ) and PD-RBD(-) with a contralateral striatal anterior-posterior gradient was 0.706 (95% CI: 0.562-0.851, P=0.016), with the sensitivity and specificity of 59.4%(19/32) and 16/18, respectively. Conclusions:The decrease of contralateral striatal anterior-posterior gradient of VMAT2 is more obvious in patients with PD-RBD(+ ), and there are differences in brain metabolism between the two groups, suggesting that there may be different neuropathological changes and different pathophysiological mechanisms between PD patients with and without RBD. 18F-DTDZ PET/CT can provide imaging basis for the differential diagnosis of the disease subtypes.